Commentary: Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders

Commentary: Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders

Bibliographic Details
Main Authors:	David A. Isenberg, Amy H. Kao, Aida Aydemir, Joan T. Merrill
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-11-01
Series:	Frontiers in Immunology
Subjects:	BAFF APRIL TACI B cell monoclonal antibody multiple sclerosis
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2020.592639/full

Similar Items

Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders
by: Celine Kaegi, et al.
Published: (2020-03-01)

Expression of B-cell activating factor, a proliferating inducing ligand and its receptors in primary central nervous system lymphoma
by: Tobias Birnbaum, et al.
Published: (2013-03-01)

Uncovering an Adipocyte’s Perspective of Inflammation and Immunity in Obesity
by: Chan, Calvin
Published: (2019)

Altered expression profile of BAFF receptors on peripheral blood B lymphocytes in Graves’ disease
by: Xin Wang, et al.
Published: (2021-04-01)

Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date
by: Lenert A, et al.
Published: (2017-03-01)

Anomalies in humoral immunity in the NOD mouse : contribution to the progression of type 1 diabetes
by: Thyagarajan, Radha
Published: (2016)

The TNFSF Members APRIL and BAFF and Their Receptors TACI, BCMA, and BAFFR in Oncology, With a Special Focus in Breast Cancer
by: Marilena Kampa, et al.
Published: (2020-06-01)

Case Report: In Situ Expression of a Proliferation-Inducing Ligand in Neuromyelitis Optica
by: Laurie Baert, et al.
Published: (2021-08-01)

High APRIL Levels Are Associated With Slow Disease Progression and Low Immune Activation in Chronic HIV-1-Infected Patients
by: Yubin Liu, et al.
Published: (2020-07-01)

Tuberculosis increases the survival of B-cells through the BAFF system molecules in HIV patients
by: Asante, Phoebe Ohemah
Published: (2021)

Bioinformatic Prediction of miRNAs Targeting APRIL and BAFF Genes in Chronic Lymphocytic Leukemia
by: Mahdieh Mondanizadeh, et al.
Published: (2019-11-01)

BAFF, APRIL, and their receptors: physiological role and involvement in the pathogenesis of chronic lymphocytic leukemia
by: Katarzyna Schab, et al.
Published: (2018-09-01)

B Cell Dysregulation in Common Variable Immunodeficiency Interstitial Lung Disease
by: Erik M. Matson, et al.
Published: (2021-02-01)

B cells targeting therapy in the management of systemic lupus erythematosus
by: Wen Shi Lee, et al.
Published: (2020-01-01)

ROLE DES MEMBRES DE LA FAMILLE BAFF/APRIL DANS LE MYELOME MULTIPLE : IMPLICATIONS PHYSIOPATHOLOGIQUES ET INTERET THERAPEUTIQUE
by: Moreaux, Jérome
Published: (2006)

Expression of BAFF, APRIL, and cognate receptor genes in lupus nephritis and potential use as urinary biomarkers
by: David Aguirre-Valencia, et al.
Published: (2020-01-01)

CLINICAL SIGNIFICANCE OF BAFF/BLyS AND APRIL IN SYSTEMIC LUPUS ERYTHEMATOSUS AND RHEUMATOID ARTHRITIS
by: E. V. Suponitskya, et al.
Published: (2014-10-01)

CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation
by: Kowarik Markus C, et al.
Published: (2012-05-01)

CLINICAL VALUE OF BAFF AND APRIL CONCENTRATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS
by: T. A. Panafidina, et al.
Published: (2016-07-01)

Association of Common Variants of <i>TNFSF13</i> and <i>TNFRSF13B </i>Genes with CLL Risk and Clinical Picture, as Well as Expression of Their Products—APRIL and TACI Molecules
by: Monika Jasek, et al.
Published: (2020-10-01)

BCMA (TNFRSF17) Induces APRIL and BAFF Mediated Breast Cancer Cell Stemness
by: Vasiliki Pelekanou, et al.
Published: (2018-08-01)

TACI Contributes to Plasmodium yoelii Host Resistance by Controlling T Follicular Helper Cell Response and Germinal Center Formation
by: Marcela Parra, et al.
Published: (2018-11-01)

The comparative efficacy and safety of anti-CD20 monoclonal antibodies for relapsing-remitting multiple sclerosis: A network meta-analysis
by: Mohammad Z.I. Asha, et al.
Published: (2021-12-01)

Modifications of the BAFF/BAFF-Receptor Axis in Patients With Pemphigus Treated With Rituximab Versus Standard Corticosteroid Regimen
by: Vivien Hébert, et al.
Published: (2021-05-01)

Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
by: Celine Kaegi, et al.
Published: (2019-09-01)

Transmembrane Activator and CAML Interactor (TACI): Another Potential Target for Immunotherapy of Multiple Myeloma?
by: Shengli Xu, et al.
Published: (2020-04-01)

TACI Mutations in Primary Antibody Deficiencies: A Nationwide Study in Greece
by: Ioannis Kakkas, et al.
Published: (2021-08-01)

Editorial: The Tumor Necrosis Factor Superfamily: An Increasing Role in Breast Cancer
by: Dirk Geerts, et al.
Published: (2020-12-01)

The Effect of Ocrelizumab in the Treatment of Multipl Sclerosis
by: Şenay Yıldız Çelik
Published: (2017-09-01)

A proliferation inducing ligand (APRIL), une molécule, deux fonctions opposées dans l'autoimmunité
by: Baert, Laurie
Published: (2019)

BAFF promotes T cell activation through the BAFF-BAFF-R-PI3K-Akt signaling pathway
by: Shanshan Hu, et al.
Published: (2019-06-01)

Increase of Intracellular BAFF in B Cells of Sjögren’s Patients Is Not Affected by Decrease of BAFFR
by: Jan Krejsek, et al.
Published: (2015-07-01)

Safety issues of monoclonal antibodies used in rheumatology
by: A. V. Philippova, et al.
Published: (2020-01-01)

Characteristics of the patients followed with the diagnosis of common variable immunodeficiency and the complications
by: Semiha Bahceci Erdem, et al.
Published: (2019-07-01)

TACI Isoforms Regulate Ligand Binding and Receptor Function
by: Yolanda Garcia-Carmona, et al.
Published: (2018-10-01)

Corrigendum: TACI Isoforms Regulate Ligand Binding and Receptor Function
by: Yolanda Garcia-Carmona, et al.
Published: (2019-12-01)

Using Monoclonal Antibody Therapies for Multiple Sclerosis: A Review
by: Elsbernd PM, et al.
Published: (2021-06-01)

Hematopoietic Stem Cell Transplantation in Neuromyelitis Optica-Spectrum Disorders (NMO-SD): State-of-the-Art and Future Perspectives
by: Giulia Ceglie, et al.
Published: (2020-07-01)

Immunological Aspects of Approved MS Therapeutics
by: Paulus S. Rommer, et al.
Published: (2019-07-01)

Ocrelizumab as a breakthrogh in multiple sclerosis treatment
by: Marcin Zaniuk, et al.
Published: (2021-05-01)

Cannot write session to /tmp/vufind_sessions/sess_3gtjdv35jjqi34e9kg9sv1jh3k